Multi link zeta

All procedural decisions, including device selection and adjunctive pharmacotherapy, were made at the discretion of the individual PCI operator. Procedural success was defined as residual stenosis < 20% without major complications. All patients received 81 or 100 mg/day of aspirin for at least 24 h before the procedure. Dual antiplatelet therapy (aspirin [81 or 100 mg] and 200 mg of ticlopidine or 75 mg of clopidogrel) was given to all patients treated with BMS for 4 weeks and in those treated with DES for at least 12 months. Glycoprotein (GP) IIb/IIIa inhibitors were not used, because they had not been approved in Japan. The following types of BMS were implanted: Multi-Link ZETA (Abbott Vascular, Santa Clara, CA) 4 patients; Duraflex (Avantec Vascular, Sunnyvale, CA) 9 patients; Driver (Medtronic, Shoreview, MN) 19 patients; and Express (Boston Scientific Corporation, Natick, MA) 12 patients. In the DES group, Cypher (Cordis, Johnson & Johnson, Miami Lakes, FL) was the only type of DES used.